2 ASX healthcare shares analysts rate highly

Looking for healthcare options? Check out these shares…

| More on:
Young doctor raising arms in air with hands in fists celebrating a new development

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

Due to ageing populations and improving technologies and treatments, demand for healthcare services is expected to grow strongly over the next few decades.

As a result, the healthcare sector could be a good place to consider investing with a long term view. But which shares should you buy? Two highly rated healthcare shares to consider are listed below:

Healius Ltd (ASX: HLS)

The first healthcare share to look at is Healius. It is one of Australia's largest pathology and diagnostic imaging providers offering services via numerous brands. These include Dorevitch Pathology, QML Pathology, Laverty Pathology, and Healthcare Imaging Services.

Healius has been a particularly positive performer in FY 2021, reporting a 16% increase in first half revenue to $953.5 million. Things were even better on the bottom line, with first half net profit growing 190% to $75.6 million. This was driven by a very strong performance by its key pathology business, which reported a 22% increase in revenue to $711.4 million and wider margins.

More of the same is expected in the second half, with a bumper full year results being forecast by brokers in August. One of those is Macquarie, which is very bullish on its prospects. The broker currently has an outperform rating and $4.85 price target on its shares.

Nanosonics Ltd (ASX: NAN)

Another healthcare share to consider is Nanosonics. It is a leading infection prevention company behind the popular trophon EPR ultrasound probe disinfection system and associated consumables and accessories.

At present, the company estimates that 80,000 patients are protected from the risk of cross contamination each day because the ultrasound probe has been high-level disinfected with trophon.

Nanosonics has also been researching and developing a number of secretive products, which are due to be launched in the coming years. One of these has just been revealed and is AuditPro. It is a digital platform that has been designed to improve traceability, reporting, and compliance of infection prevention measures for medical devices.

The first focus will be on marketing it as a solution for the ultrasound market, with potential for the new product to be coupled with every ultrasound console at point of care.

One broker that is very positive on its prospects is Morgans. According to a recent note, the broker has an add rating and $6.57 price target on its shares.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Nanosonics Limited. The Motley Fool Australia owns shares of and has recommended Nanosonics Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

3 ASX companies that are global leaders

Numerous ASX companies have extended their reach beyond Australia to dominate in their fields.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Bell Potter just slapped a buy on this ASX 200 share offering a 30% return

Which stock is being tipped as a buy? Let's find out.

Read more »

Happy healthcare workers in a labs
Healthcare Shares

Macquarie initiates coverage of Neuren Pharmaceuticals shares; forecasts 45% upside

The broker described Neuren as a standout in the ASX biotech sector.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
Healthcare Shares

Does Macquarie think Cochlear shares are a buy, hold, or sell?

Macquarie has released a new note on Cochlear following the company's FY25 profit guidance change.

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

Up 18% this year, does Macquarie expect NIB shares to go higher?

This expert has a bold prediction for NIB.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why is the Mesoblast share price up 11% in June?

The ASX biotech share reached a 10-week high of $1.94 today.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Up 51% since the tariff pain, is it too late to buy Pro Medicus shares?

After rocketing higher, is the ASX healthcare share still an opportunity?

Read more »

A woman wearing a yellow shirt smiles as she checks her phone.
Healthcare Shares

CSL shares push higher on US FDA approval

This biotech giant has been given a boost in the United States.

Read more »